165 related articles for article (PubMed ID: 8562906)
41. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
42. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
[TBL] [Abstract][Full Text] [Related]
43. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
[TBL] [Abstract][Full Text] [Related]
44. Recombinant single-chain immunotoxins against T and B cell leukemias.
Kreitman RJ; Pastan I
Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
[TBL] [Abstract][Full Text] [Related]
45. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
Hassan R; Viner JL; Wang QC; Margulies I; Kreitman RJ; Pastan I
J Immunother; 2000; 23(4):473-9. PubMed ID: 10916757
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
47. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice.
Benhar I; Reiter Y; Pai LH; Pastan I
Int J Cancer; 1995 Jul; 62(3):351-5. PubMed ID: 7628878
[TBL] [Abstract][Full Text] [Related]
48. Biotechnological and gene therapeutic strategies in cancer treatment.
Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
[TBL] [Abstract][Full Text] [Related]
49. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
Du X; Ho M; Pastan I
J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
[TBL] [Abstract][Full Text] [Related]
50. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus.
Davey RT; Boenning CM; Herpin BR; Batts DH; Metcalf JA; Wathen L; Cox SR; Polis MA; Kovacs JA; Falloon J
J Infect Dis; 1994 Nov; 170(5):1180-8. PubMed ID: 7963711
[TBL] [Abstract][Full Text] [Related]
51. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
[TBL] [Abstract][Full Text] [Related]
52. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
Benhar I; Pastan I
J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
[TBL] [Abstract][Full Text] [Related]
53. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
Pearson JW; Hedrick E; Fogler WE; Bull RL; Ferris DK; Riggs CW; Wiltrout RH; Sivam G; Morgan AC; Groves E
Cancer Res; 1990 Oct; 50(19):6379-88. PubMed ID: 2144790
[TBL] [Abstract][Full Text] [Related]
54. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
[TBL] [Abstract][Full Text] [Related]
55. Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells.
Batra JK; FitzGerald D; Gately M; Chaudhary VK; Pastan I
J Biol Chem; 1990 Sep; 265(25):15198-202. PubMed ID: 2118522
[TBL] [Abstract][Full Text] [Related]
56. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses.
Kreitman RJ; Pastan I
Cancer Res; 1998 Mar; 58(5):968-75. PubMed ID: 9500458
[TBL] [Abstract][Full Text] [Related]
57. Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer.
Myklebust AT; Godal A; Fodstad O
Cancer Res; 1994 Apr; 54(8):2146-50. PubMed ID: 8174121
[TBL] [Abstract][Full Text] [Related]
58. Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.
Wang G; Kumar A; Ding W; Korangath P; Bera T; Wei J; Pai P; Gabrielson K; Pastan I; Sukumar S
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2200200119. PubMed ID: 35675429
[TBL] [Abstract][Full Text] [Related]
59. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme.
Hjortland GO; Garman-Vik SS; Juell S; Olsen OE; Hirschberg H; Fodstad O; Engebraaten O
J Neurosurg; 2004 Feb; 100(2):320-7. PubMed ID: 15086240
[TBL] [Abstract][Full Text] [Related]
60. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.
Batra JK; Jinno Y; Chaudhary VK; Kondo T; Willingham MC; FitzGerald DJ; Pastan I
Proc Natl Acad Sci U S A; 1989 Nov; 86(21):8545-9. PubMed ID: 2510169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
